Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study.

Krebs MG, Cho BC, Hiret S, Han JY, Lee KH, Pérez CL, De Braud F, Haura EB, Sanborn RE, Chih-Hsin Yang J, Shu CA, Goto K, Nishio M, Zhao J, Wang Z, Tomasini P, Felip E, Goldman JW, Ou SI, Boyer M, Gao G, Qu S, Curtin JC, Lyu X, Schnepp RW, Kim P, Thayu M, Knoblauch RE, Lorenzini P, Baig M, Spira AI, Leighl NB

Open source

DOI: 10.1016/j.jtho.2025.05.012
Published: 2025 Sep
Container: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jtho.2025.05.012,
  title = {Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study.},
  author = {Krebs MG and Cho BC and Hiret S and Han JY and Lee KH and Pérez CL and De Braud F and Haura EB and Sanborn RE and Chih-Hsin Yang J and Shu CA and Goto K and Nishio M and Zhao J and Wang Z and Tomasini P and Felip E and Goldman JW and Ou SI and Boyer M and Gao G and Qu S and Curtin JC and Lyu X and Schnepp RW and Kim P and Thayu M and Knoblauch RE and Lorenzini P and Baig M and Spira AI and Leighl NB},
  year = {2025},
  journal = {Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  doi = {10.1016/j.jtho.2025.05.012},
  url = {https://doi.org/10.1016/j.jtho.2025.05.012}
}

RIS

TY  - JOUR
TI  - Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study.
AU  - Krebs MG
AU  - Cho BC
AU  - Hiret S
AU  - Han JY
AU  - Lee KH
AU  - Pérez CL
AU  - De Braud F
AU  - Haura EB
AU  - Sanborn RE
AU  - Chih-Hsin Yang J
AU  - Shu CA
AU  - Goto K
AU  - Nishio M
AU  - Zhao J
AU  - Wang Z
AU  - Tomasini P
AU  - Felip E
AU  - Goldman JW
AU  - Ou SI
AU  - Boyer M
AU  - Gao G
AU  - Qu S
AU  - Curtin JC
AU  - Lyu X
AU  - Schnepp RW
AU  - Kim P
AU  - Thayu M
AU  - Knoblauch RE
AU  - Lorenzini P
AU  - Baig M
AU  - Spira AI
AU  - Leighl NB
PY  - 2025
JO  - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
DO  - 10.1016/j.jtho.2025.05.012
UR  - https://doi.org/10.1016/j.jtho.2025.05.012
ER  -

APA

MG, K., BC, C., S, H., JY, H., KH, L., CL, P., F, D. B., EB, H., RE, S., J, C. Y., CA, S., K, G., M, N., J, Z., Z, W., P, T., E, F., JW, G., SI, O., M, B., G, G., S, Q., JC, C., X, L., RW, S., P, K., M, T., RE, K., P, L., M, B., AI, S., & NB, L. (2025). Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. https://doi.org/10.1016/j.jtho.2025.05.012

Source records

pubmed · retrieved 2026-09-25T19:25:47.171Z